# Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

> **NCT05704933** · EARLY_PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 1 (actual)

## Conditions studied

- Metastatic Melanoma
- Metastasis to Brain

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab + Relatlimab
- **PROCEDURE:** Standard of Care Craniotomy

## Key facts

- **NCT ID:** NCT05704933
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-06
- **Primary completion:** 2024-06-07
- **Final completion:** 2024-08-20
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05704933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05704933, "Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05704933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*